NASDAQ
Cartesian Therapeutics, Inc. (RNAC)
♥ 524 Thanks from members
Cartesian Therapeutics, Inc. (RNAC) exhibits strong bullish market sentiment driven by late-stage progress of its RNA-engineered CAR-T therapy, Descartes-08, in myasthenia gravis, robust institutional backing with a $35-$38 price target range, and strengthened cash runway extending into 2028.